Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume – What’s Next?

Pharming Group (NASDAQ:PHAR) saw unusually-high trading volume on Friday . Approximately 2,626 shares traded hands during mid-day trading, a decline of 46% from the previous session’s volume of 4,869 shares.The stock last traded at $8.72 and had previously closed at $8.30.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a research note on Thursday.

Pharming Group Stock Performance

The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.65 and a current ratio of 3.39. The stock has a fifty day simple moving average of $8.05 and a two-hundred day simple moving average of $8.54. The stock has a market cap of $590.12 million, a PE ratio of -45.79 and a beta of 0.15.

Pharming Group (NASDAQ:PHAR) last announced its earnings results on Thursday, August 1st. The company reported ($0.01) earnings per share for the quarter. The firm had revenue of $74.09 million during the quarter, compared to analysts’ expectations of $71.95 million. Pharming Group had a negative net margin of 4.65% and a negative return on equity of 5.69%. During the same quarter last year, the company posted $0.02 earnings per share. Equities analysts anticipate that Pharming Group will post -0.15 EPS for the current fiscal year.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its holdings in Pharming Group (NASDAQ:PHAR) by 75.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 41,110 shares of the company’s stock after purchasing an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned about 0.06% of Pharming Group worth $339,000 at the end of the most recent reporting period. 0.03% of the stock is owned by hedge funds and other institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.